Prepare for Liftoff: Alphabet's Moonshot Projects Primed and Set to Soar

Embracing the upcoming autumn harvest season, Alphabet (GOOGL.O) is gearing up for exciting changes. Ruth Porat, the dynamic Chief Financial Officer of the tech giant and a former tech investment banker at Morgan Stanley (MS.N), is embarking on a new journey next month. Her role will expand to include the oversight of "other bets," an intriguing array of experimental projects. It's an opportune moment to reevaluate and revamp the innovative portfolio.

Signs of transformation are already evident at Verily Life Sciences, the health-data whiz that raked in a remarkable $560 million in revenue last year, as highlighted in a recent report by the Wall Street Journal. This impressive sum constituted over half of the non-search division's $1 billion contributions. For context, in 2022, Alphabet's total revenue exceeded $280 billion, yielding a net profit of $60 billion, while the "other bets" incurred a loss of $6 billion.

Amidst its nearly doubled top-line growth this year, Verily is experiencing a rise in operating costs, according to tech experts at The Information. In response, Stephen Gillett, Verily's leader, shared plans to disentangle from certain Alphabet services in the coming year. This strategic decision sparks speculation of a potential spinoff. Notably, Verily has already attracted external investments, including from Singapore's wealth fund Temasek.

From Alphabet's perspective, letting Verily take flight independently seems logical. Initially nurtured to develop a cancer-detection pill, Verily now predominantly generates revenue by offering insurance products to employers. This shift into financial services falls outside Alphabet's traditional realm. Moreover, as the tech world refocuses on artificial intelligence, wise capital allocation becomes crucial. In fact, Chris Hohn's activist TCI Fund Investments conveyed this sentiment to the $1.6 trillion conglomerate last year.

The lineup of "other bets" is brimming with prospects for potential separation. Waymo, the self-driving technology venture, recently secured approval to launch driverless rideshares in San Francisco, marking a significant achievement. Furthermore, the turmoil in this sector has swept away rivals like Ford Motor's (F.N) similar business. After a period of dormancy, Google Fiber, the internet provider, intends to expand again, spelling renewed promise for Alphabet's experimental endeavors.

Nonetheless, some speculative endeavors could emerge as pivotal sources of enduring growth. A case in point is the strategic relocation of DeepMind, an AI venture previously housed under "other bets," into Google's fold earlier this year. This move underscores Alphabet's commitment to nurturing unproven, nascent concepts and fostering their growth. This approach gains significance as regulatory bodies scrutinize tech giants' expansion through acquisitions. Some moonshots are simply destined for liftoff.

Verily Life Sciences is charting a course towards independence, aiming to sever ties with parent company Alphabet's services, as revealed by Chief Executive Stephen Gillett. The technology publication, The Information, reported this on August 18.

This health-focused unit encountered an operating loss for the first half of 2023, surpassing its projections by $17 million, according to an internal presentation detailed by the Wall Street Journal on August 16. In 2022, Verily recorded a loss of $568 million despite generating $559 million in revenue, the newspaper disclosed.

Source : Reuters (Reporting by Anita Ramaswamy)